Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastas… (NCT06716775) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
200 participantsStarted 2024-12-20
Plain-language summary
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the treatment of brain metastases from non-small cell lung cancer (NSCLC) .
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The age of the subject was between 18 and 75 years old (inclusive), regardless of gender;
✓. Karnofsky performance status (KPS) score ≥70;
✓. Able to operate the TTF independently or with the help of a caregiver;
✓. Subjects of childbearing potential had to agree to use effective contraception for the duration of the trial;
✓. Voluntarily signed the informed consent form.
Exclusion criteria
✕. Positive driver genes;
✕. Recurrent brain metastasis of NSCLC;
✕. Suffering from severe cerebral edema;
✕. Leptomeningeal metastases;
✕. Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following: